Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 1
2008 3
2009 3
2010 1
2011 2
2012 3
2013 4
2014 7
2015 7
2016 5
2017 6
2018 12
2019 10
2020 11
2021 14
2022 12
2023 13
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, Rampal RK, Mead AJ, Hobbs G, Scandura JM, Talpaz M, Granacher N, Somervaille TCP, Hoffman R, Wondergem MJ, Salama ME, Colak G, Cui J, Kiladjian JJ, Vannucchi AM, Verstovsek S, Curto-García N, Harrison C, Gupta V. Mascarenhas J, et al. Among authors: wondergem mj. J Clin Oncol. 2023 Nov 10;41(32):4993-5004. doi: 10.1200/JCO.22.01972. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881782 Free PMC article. Clinical Trial.
Reply by Authors.
Meijer D, Luiting HB, van Leeuwen PJ, Remmers S, Jansen BHE, Bodar YJL, Witteveen T, Schaake EE, van der Poel HG, Wondergem M, Busstra MB, Nieuwenhuijzen JA, Meijnen P, Brabander T, van Moorselaar RJA, Hendrikse NH, Oprea-Lager DE, Roobol MJ, Vis AN. Meijer D, et al. Among authors: wondergem m. J Urol. 2021 Apr;205(4):1108-1109. doi: 10.1097/JU.0000000000001437.02. Epub 2021 Jan 25. J Urol. 2021. PMID: 33493004 No abstract available.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Harrison CN, et al. Among authors: wondergem mj. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11. Future Oncol. 2022. PMID: 35950489
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
Veringa A, Brüggemann RJ, Span LFR, Biemond BJ, de Boer MGJ, van den Heuvel ER, Klein SK, Kraemer D, Minnema MC, Prakken NHJ, Rijnders BJA, Swen JJ, Verweij PE, Wondergem MJ, Ypma PF, Blijlevens N, Kosterink JGW, van der Werf TS, Alffenaar JC; Voriconazole ZonMw Study Group. Veringa A, et al. Among authors: wondergem mj. Int J Antimicrob Agents. 2023 Feb;61(2):106711. doi: 10.1016/j.ijantimicag.2023.106711. Epub 2023 Jan 13. Int J Antimicrob Agents. 2023. PMID: 36642232 Free article. Clinical Trial.
Genotyping by morphology..
Wondergem MJ, Ossenkoppele GJ. Wondergem MJ, et al. Blood. 2011 Mar 3;117(9):2566. doi: 10.1182/blood-2010-04-282244. Blood. 2011. PMID: 21488251 Free article. No abstract available.
[A woman with gingival enlargement].
Castelijn DAR, Wondergem MJ, Heijink DM. Castelijn DAR, et al. Among authors: wondergem mj. Ned Tijdschr Geneeskd. 2021 Feb 3;165:D5632. Ned Tijdschr Geneeskd. 2021. PMID: 33651523 Dutch.
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, Devos T, Krochmalczyk D, Galli S, Bieniaszewska M, Seferynska I, McMullin MF, Armatys A, Spalek A, Waclaw J, Zdrenghea M, Legros L, Girodon F, Lewandowski K, Angona Figueras A, Samuelsson J, Abuin Blanco A, Cony-Makhoul P, Collins A, James C, Kusec R, Lauermannova M, Noya MS, Skowronek M, Szukalski L, Szmigielska-Kaplon A, Wondergem M, Dudchenko I, Gora Tybor J, Laribi K, Kulikowska de Nalecz A, Demory JL, Le Du K, Zweegman S, Besses Raebel C, Skoda R, Giraudier S, Griesshammer M, Harrison CN, Ianotto JC. Sobas M, et al. Among authors: wondergem m. Blood Adv. 2022 Sep 13;6(17):5171-5183. doi: 10.1182/bloodadvances.2022007201. Blood Adv. 2022. PMID: 35802458 Free PMC article.
105 results